Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment

Erdem Tüzün, Matthew N. Meriggioli, Julie Rowin, Huan Yang, Premkumar Christadoss

Research output: Contribution to journalArticle

51 Scopus citations

Abstract

Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-γ. There was a direct correlation between plasma IL-6, TNF-α and IFN-γ levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-γ levels attained better clinical improvement following etanercept treatment.

Original languageEnglish (US)
Pages (from-to)261-268
Number of pages8
JournalJournal of Autoimmunity
Volume24
Issue number3
DOIs
StatePublished - May 2005

Keywords

  • Autoimmunity
  • Etanercept
  • Interferon-γ
  • Interleukin-6
  • Myasthenia gravis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment'. Together they form a unique fingerprint.

  • Cite this